TICKERNERD
Menu
LQDALQDAHealthcare · Drug Manufacturers - Specialty & Generic

LQDA Stock Forecast: Liquidia Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$74
+3.25% on the day

The 8 Wall Street analysts covering Liquidia Corp. hold a median 12-month price target of $109 — +46.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$6.7B
Ticker Nerd rank
78 / 100
Median analyst target
$109
Analysts covering
8
Total return, dividends reinvested
1W
−17.5%
1M
−2.7%
YTD
+115.8%
1Y
+185.3%
From 52W high
−18.2%
From 52W low
+241.5%
$22
$91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LQDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Liquidia Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
100
Momentum
98
Growth
97
Value
96
Volatility
73
Revisions
47
Accruals
27
Size
21
Issuance
17

Quality (100): The business earns solid, repeatable profits on what it owns.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LQDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LQDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26LQDAHigh $130Median $109Low $90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
6 Buy2 Hold0 Sell
Low $90Median $109High $130

The green dot is the last close — the median target sits +46.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 18 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Aug 2026B of A SecuritiesMaintainsNeutral$79 → $92
13 Aug 2026Wells FargoMaintainsOverweight$62 → $108
12 Aug 2026BTIGMaintainsBuy$109 → $111
12 Aug 2026LifeSci CapitalDowngradeMarket Perform$90
12 Aug 2026NeedhamMaintainsBuy$70 → $110
23 July 2026HC Wainwright & Co.MaintainsBuy$75 → $130
29 June 2026B of A SecuritiesDowngradeNeutral$64 → $79
22 June 2026BTIGMaintainsBuy$59 → $109
5 June 2026HC Wainwright & Co.MaintainsBuy$67 → $75
12 May 2026HC Wainwright & Co.MaintainsBuy$55 → $67
12 May 2026Wells FargoMaintainsOverweight$51 → $62
11 May 2026BTIGMaintainsBuy$50 → $59
11 May 2026NeedhamMaintainsBuy$54 → $70
23 Mar 2026Wells FargoMaintainsOverweight$44 → $51
12 Mar 2026OppenheimerMaintainsUnderperform$16 → $19
6 Mar 2026HC Wainwright & Co.MaintainsBuy$50 → $55
6 Mar 2026Wells FargoMaintainsOverweight$31 → $44
5 Mar 2026BTIGMaintainsBuy$49 → $50
5 Mar 2026NeedhamMaintainsBuy$52 → $54
25 Feb 2026NeedhamReiteratesBuy$52

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LQDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LQDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+35.0%
Analysts raising
0
Analysts cutting
0
Fundamentals

Liquidia Corp. (LQDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
53.2×

Cheaper than 14% of US stocks

Price / sales
14.8×

Cheaper than 11% of US stocks

Price / book
60.5×

Cheaper than 2% of US stocks

EV / EBITDA
38.7×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
1842.7%

Higher than 99% of US stocks

Earnings growth (YoY)
4158.5%

Higher than 99% of US stocks

Gross margin
91.1%

Higher than 97% of US stocks

Operating margin
49.8%

Higher than 96% of US stocks

Net margin
30.7%

Higher than 90% of US stocks

Returns & dividend
Return on equity
131.8%

Higher than 97% of US stocks

Return on assets
27.0%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LQDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
LQDALiquidia Corp.$6.7B
78
LNTHLantheus Holdings, Inc.$6.5B
88
HIMSHims & Hers Health, Inc.$6.6B
17
KNSAKiniksa Pharmaceuticals International Plc$5.9B
98
AMRXAmneal Pharmaceuticals, Inc.$5.7B
79
ALKSAlkermes Plc$8.1B
60
INDVIndivior Pharmaceuticals, Inc.$4.6B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Liquidia Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LQDA news & analysis

Why Liquidia Stock Was Diving This Week

The Motley Fool · 14 Aug 2026negative

Liquidia's stock was falling during the week after a significant run-up, having risen 155% year-to-date before earnings. Despite the share price decline, the company's one commercialized drug is performing well.

Why it matters — A LQDA watcher would care because the steep weekly pullback contrasts with the stock's prior strong gains and the solid performance of its only marketed drug, which could affect how the company is valued going forward.

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Zacks Investment Research · 13 Aug 2026positive

Liquidia Corp. reported Q2 earnings that topped estimates, with strong Yutrepia sales fueling top-line revenue growth and rising profitability. The company also stated it is targeting more than $1 billion in 2027 revenues.

Why it matters — A LQDA watcher would care because Yutrepia's strong sales are a key driver of the company's revenue growth and improved profitability.

LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path

Zacks Investment Research · 13 Aug 2026positive

During its Q2 earnings call, Liquidia highlighted its goal of more than $1 billion in 2027 net revenues as YUTREPIA gains market share. The company indicated the revenue would help fund a broader inhaled-treprostinil pipeline.

Why it matters — An LQDA watcher would care because the company's stated revenue target for YUTREPIA and the funding of its broader pipeline directly relate to Liquidia's commercial growth outlook.

Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow

Seeking Alpha · 13 Aug 2026positive

Liquidia's YUTREPIA commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Product gross margin held at about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%, shifting the key debate from profitability to growth, with roughly $210 million of quarterly revenue needed in Q3 and Q4 to reach the FY2026 consensus of $725 million.

Why it matters — The article indicates margin concerns were largely resolved and attention has shifted to whether YUTREPIA's growth can sustain momentum to meet future revenue targets, which is central to Liquidia's outlook.

Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Seeking Alpha published the transcript of Liquidia Corporation's (LQDA) Q2 2026 earnings call. The item provides the earnings call transcript for that quarter.

Why it matters — A LQDA watcher would want to review the Q2 2026 earnings call transcript for details on the company's quarterly results and management commentary.

FAQ

Frequently asked questions about LQDA stock

What is the LQDA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Liquidia Corp. have a median 12-month price target of $109, with estimates ranging from $90 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LQDA stock a buy right now?

Of the 8 analysts covering Liquidia Corp., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Liquidia Corp. 78 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LQDA?

As at 15 Aug 2026, Liquidia Corp. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).

Will LQDA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +46.4% from the last close, and Ticker Nerd's factor model ranks Liquidia Corp. 78 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LQDA stock forecast for 2030?

No analyst covering Liquidia Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LQDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $130 over the next 12 months.

How has LQDA stock performed over the past year?

Liquidia Corp. returned +185.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Liquidia Corp. do?

Liquidia Corporation is a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, primarily in the United States. The company develops, manufactures, and commercializes treatments aimed at addressing unmet patient needs in pulmonary hypertension.

What is the latest news on LQDA?

The most recent item we track (The Motley Fool, 14 Aug 2026): "Why Liquidia Stock Was Diving This Week". Liquidia's stock was falling during the week after a significant run-up, having risen 155% year-to-date before earnings. Despite the share price decline, the company's one commercialized drug is performing well.

Company

About Liquidia Corp.

Liquidia Corporation is a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, primarily in the United States. The company develops, manufactures, and commercializes treatments aimed at addressing unmet patient needs in pulmonary hypertension. Its key product, Yutrepia, is an inhaled dry powder formulation of treprostinil used for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, delivered via a user-friendly inhalation device to support chronic outpatient management. Liquidia also commercializes and develops treprostinil-based therapies in other formulations, including continuous infusion and investigational liposomal and inhaled sustained-release products, often under licensing collaborations. By concentrating on specialized cardiopulmonary indications and leveraging drug-delivery innovation, Liquidia plays a targeted role within the U.S. pharmaceuticals and biotech sector, serving pulmonologists, specialty clinics, and hospital systems involved in advanced respiratory and vascular care. Founded in 2004 and headquartered in Morrisville, North Carolina, the company operates within the broader healthcare ecosystem as a niche provider of advanced pulmonary hypertension treatments.

CEO Dr. Roger A. Jeffs Ph.D. · 216 employees · United States · https://www.liquidia.com